Viridian Therapeutics, Inc./DE (VRDN) ROI
- 2025-06-30: ROI -64.20%.
- 2024-12-31: ROI -39.00%.
- 2024-06-30: ROI -41.48%.
- 2023-12-31: ROI -51.43%.
Complete source-backed roi history.
- Available history
- 2023-12-31 to 2025-06-30
- Data captured
Historical ROI
| Date | ROI |
|---|---|
| 2025-06-30 | -64.20% |
| 2024-12-31 | -39.00% |
| 2024-06-30 | -41.48% |
| 2023-12-31 | -51.43% |
Annual ROI
| Date | ROI |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |